Activation of the RAS/RAF-MEK/ERK signaling pathway is required for erastin-induced cell death, while restraining RAS or its downstream signaling molecules reverses the lethality against cancer cells [30, 31]. The gene discussed is MAP2K7; the disease is cancer.